Literature DB >> 7479298

Neutral endopeptidase can hydrolyze beta-amyloid(1-40) but shows no effect on beta-amyloid precursor protein metabolism.

S Howell1, J Nalbantoglu, P Crine.   

Abstract

High performance liquid chromatographic analyses of incubations of beta-amyloid(1-40) with neutral endopeptidase revealed at least nine product peaks, indicating that neutral endopeptidase can cleave beta-amyloid at multiple sites. Mass spectroscopic analysis of hydrolyzed beta-amyloid identified at least five cleavage sites, between residues Glu3-Phe4, Gly9-Trp10, Phe19-Phe20, Ala30-Ile31, and Gly33-Leu34. In contrast, amyloid precursor protein metabolism in Neuro2A cells was unaffected by the expression of recombinant neutral endopeptidase in the same cells or by the addition of a secreted form of neutral endopeptidase to spent Neuro2A cell media.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7479298     DOI: 10.1016/0196-9781(95)00021-b

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  60 in total

1.  PACE4: a subtilisin-like endoprotease with unique properties.

Authors:  R E Mains; C A Berard; J B Denault; A Zhou; R C Johnson; R Leduc
Journal:  Biochem J       Date:  1997-02-01       Impact factor: 3.857

Review 2.  Targeting amyloid clearance in Alzheimer's disease as a therapeutic strategy.

Authors:  Natalia N Nalivaeva; Anthony J Turner
Journal:  Br J Pharmacol       Date:  2019-03-11       Impact factor: 8.739

3.  Somatostatin receptor subtype-4 agonist NNC 26-9100 decreases extracellular and intracellular Aβ₁₋₄₂ trimers.

Authors:  Karin E Sandoval; Susan A Farr; William A Banks; Albert M Crider; John E Morley; Ken A Witt
Journal:  Eur J Pharmacol       Date:  2012-03-16       Impact factor: 4.432

4.  Phosphorylation of amyloid-β peptide at serine 8 attenuates its clearance via insulin-degrading and angiotensin-converting enzymes.

Authors:  Sathish Kumar; Sandesh Singh; Désirée Hinze; Michaele Josten; Hans-Georg Sahl; Martin Siepmann; Jochen Walter
Journal:  J Biol Chem       Date:  2012-01-20       Impact factor: 5.157

5.  Insulysin hydrolyzes amyloid beta peptides to products that are neither neurotoxic nor deposit on amyloid plaques.

Authors:  A Mukherjee; E Song; M Kihiko-Ehmann; J P Goodman; J S Pyrek; S Estus; L B Hersh
Journal:  J Neurosci       Date:  2000-12-01       Impact factor: 6.167

6.  Rare Variants in MME, Encoding Metalloprotease Neprilysin, Are Linked to Late-Onset Autosomal-Dominant Axonal Polyneuropathies.

Authors:  Michaela Auer-Grumbach; Stefan Toegel; Maria Schabhüttl; Daniela Weinmann; Catharina Chiari; David L H Bennett; Christian Beetz; Dennis Klein; Peter M Andersen; Ilka Böhme; Regina Fink-Puches; Michael Gonzalez; Matthew B Harms; William Motley; Mary M Reilly; Wilfried Renner; Sabine Rudnik-Schöneborn; Beate Schlotter-Weigel; Andreas C Themistocleous; Jochen H Weishaupt; Albert C Ludolph; Thomas Wieland; Feifei Tao; Lisa Abreu; Reinhard Windhager; Manuela Zitzelsberger; Tim M Strom; Thomas Walther; Steven S Scherer; Stephan Züchner; Rudolf Martini; Jan Senderek
Journal:  Am J Hum Genet       Date:  2016-09-01       Impact factor: 11.025

Review 7.  Endothelin-converting enzymes and related metalloproteases in Alzheimer's disease.

Authors:  Javier Pacheco-Quinto; Aimee Herdt; Christopher B Eckman; Elizabeth A Eckman
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

8.  Glutamate carboxypeptidase II is not an amyloid peptide-degrading enzyme.

Authors:  Jesse Alt; Marigo Stathis; Camilo Rojas; Barbara Slusher
Journal:  FASEB J       Date:  2013-03-23       Impact factor: 5.191

9.  Zinc metalloproteinases and amyloid Beta-Peptide metabolism: the positive side of proteolysis in Alzheimer's disease.

Authors:  Mallory Gough; Catherine Parr-Sturgess; Edward Parkin
Journal:  Biochem Res Int       Date:  2010-09-30

10.  Axonal transport of neprilysin in rat sciatic nerves.

Authors:  Genki Ohkushi; Noriko Suzuki; Shigeki Kobayashi; Toshiyuki Chikuma
Journal:  J Mol Neurosci       Date:  2013-12-22       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.